This systematic review was designed to provide more precise effect estimates of inhibitor
development for the various types of F8 gene mutations in patients with severe hemophilia …

Focuses on clinical features, laboratory diagnosis, prognostic factors and therapeutic
management of patients with acquired hemophilia. Association of acquired hemophilia with …

Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing
autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without …

Current treatments to control pathological or unwanted immune responses often use broadly
immunosuppressive drugs. New approaches to induce antigen-specific immunological …

Background: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by
autoantibodies against coagulation factor VIII and characterized by spontaneous …

Background Effective ways to prevent arthropathy in severe hemophilia are unknown.
Methods We randomly assigned young boys with severe hemophilia A to regular infusions …

Information was obtained by questionnaire about 215 nonhemophilic patients who
developed inhibitors against factor VIII (antihemophilic factor). The majority of the patients …

Antibodies against factor VIII coagulant activity can appear in haemophiliacs who are treated
with factor VIII preparations but also spontaneously in non-haemophiliacs. The Bethesda …

Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies
directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history …

A complete copy of the mRNA sequences encoding human coagulation factor VIII: C has
been cloned and expressed. The DNA sequence predicts a single chain precursor of 2,351 …